NCT00485771已完成4 期
Olanzapine/Fluoxetine Combination Versus Lamotrigine in the Treatment of Bipolar I Depression
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 403
- 试验地点
- 1
- 主要终点
- Assess the efficacy of olanzapine/fluoxetine combination compared with lamotrigine in the treatment of patients with bipolar I depression during the first 7 weeks of therapy.
研究概览
简要总结
The purpose of this study is to assess olanzapine/fluoxetine combination and lamotrigine comparative efficacy, safety and tolerability in acute and longer term treatment of bipolar depression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients, 18 to 60 years of ages, inpatients or outpatients. Inpatients are qualified only if they are hospitalized for current episode of bipolar depression and should be able to leave hospital when clinical criteria are no longer met for acute inpatient hospitalization
- •Patients must fulfill the criteria for bipolar I depression (bipolar I disorder, current episode major depressive) as defined in DSM-IV-TR based on clinical examination and psychiatric assessment
- •Patients must have experienced, in the opinion of the investigator, at least one previous manic or mixed episode as defined in DSM-IV-TR, of sufficient severity to require treatment with a mood stabilizer or an antipsychotic as reported by the patient or the caregiver
- •Each patient must have a level of understanding sufficient to perform all tests and examinations required by the protocol
- •Female patients must test negative for pregnancy and must be using a medically accepted means of contraception
排除标准
- •Current diagnosis of any of the following according to DSM-IV-TR criteria: Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Delirium of any type, Dementia of any type, Amnestic Disorder, any Substance-Induced Disorder, or any Psychotic Disorder due to a General Medical Condition, unless there is substantive reason to believe patient was previously misdiagnosed.
- •Treatment with clozapine within 3 months (90 days) prior to visit 1
- •Treatment with electroconvulsive therapy (ECT) within 3 months (90 days) prior to visit 2
- •Patients with seizure disorders are excluded (except patients with a previous history of seizures due to alcohol withdrawal, which have resolved).
- •Participation in a clinical trial of another drug including olanzapine, fluoxetine or lamotrigine within 30 days prior to study entry (visit 1)
结局指标
主要结局
Assess the efficacy of olanzapine/fluoxetine combination compared with lamotrigine in the treatment of patients with bipolar I depression during the first 7 weeks of therapy.
次要结局
- Assess the efficacy of olanzapine/fluoxetine combination compared with lamotrigine on depressive symptoms
- Assess the onset of action of olanzapine/fluoxetine combination compared with lamotrigine as measured by time to achieve an initial response
- Assess the study-defined response and remission rates including time to achieve a full response and time to achieve remission as well as time to sustained response and sustained remission
- Assess the time to and rate of relapse to depressive episode following remission for olanzapine/fluoxetine combination compared with lamotrigine
- Assess the time to and rate of relapse to mania with olanzapine/fluoxetine combination compared with lamotrigine
- Assess efficacy of treatment in improving symptomatology
- Evaluate the level of health resource utilization and resource utilization costs associated with olanzapine/fluoxetine combination compared with lamotrigine during the study treatment period
- Assess the efficacy of olanzapine/fluoxetine combination compared with lamotrigine for suicide ideation
- Assess the total time of hospitalization of patients on olanzapine/fluoxetine combination compared with lamotrigine during the study treatment period
- Assess the safety and tolerability of olanzapine/fluoxetine combination compared with lamotrigine during 6 months of therapy
- The sensitivity and positive predictive value of the MDQ will be determined in this study, using the SCID as a standard
- To explore possible correlation between changes in eating behavior and changes in body weight
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant DepressionMajor Depressive DisorderNCT00035321Eli Lilly and Company600
已完成
4 期
Olanzapine Compared to Lamotrigine in the Prevention of Depressive Episode in the Patients With Bipolar DisorderBipolar DisorderNCT01864551Tri-Service General Hospital60
已完成
4 期
Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment ResponseDepression, BipolarNCT00191399Eli Lilly and Company150
已完成
3 期
A Study in Relapse Prevention of Treatment-Resistant DepressionTreatment Resistant DepressionNCT00958568Eli Lilly and Company892
终止
3 期
A Study of Olanzapine and Fluoxetine for Treatment-resistant DepressionTreatment Resistant DepressionNCT01687478Eli Lilly and Company176